Glucagon‐like peptide‐1 (GLP‐1) agonists were initially designed as a medication for diabetes [6], but these agents are also efficient for weight loss in patients with obesity [7]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.